TY - JOUR T1 - Impact of Bevacizumab <em>Versus</em> Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group JF - Anticancer Research JO - Anticancer Res SP - 2095 LP - 2106 DO - 10.21873/anticanres.14168 VL - 40 IS - 4 AU - GIANNIS MOUNTZIOS AU - XANTHIPPI MAVROPOULOU AU - GEORGIA-ANGELIKI KOLIOU AU - HELENA LINARDOU AU - EPAMINONTAS SAMANTAS AU - PARIS KOSMIDIS AU - GEORGE FOUNTZILAS AU - APHRODITE CHARITANDI AU - ANNA KALOGERA-FOUNTZILA Y1 - 2020/04/01 UR - http://ar.iiarjournals.org/content/40/4/2095.abstract N2 - Background: The mechanism of action of bevacizumab and erlotinib is quite different in the treatment of advanced non-small cell lung cancer (NSCLC). This study sought to compare the two targeted therapies in terms of sequential tumor response metrics. Patients and Methods: Parameters of radiological tumor response evaluation were assessed at baseline and periodically in 58 patients receiving either bevacizumab plus platinum-based chemotherapy (N=25) or erlotinib (N=33). Results: Bevacizumab-treated patients had lower longest diameter at best response compared to the erlotinib group (p=0.011). The longest diameter, tumor volume and density significantly decreased from baseline to best response for the entire cohort and bevacizumab-treated patients; no difference was found in the erlotinib group. Conclusion: Treatment with bevacizumab substantially improved tumor metrics between baseline and each cycle of treatment, as well as between baseline and best response, in patients with advanced NSCLC. ER -